PD-1/PD-L1

PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitor anticancer drugs that block the activity of PD-1 and PDL1 immune checkpoint proteins present on the surface of cells. Immune checkpoint inhibitors are emerging as a front-line treatment for several types of cancer.

Cat. No.	Product name	CAS No.	Purity
T36900	PD-1/PD-L1-IN-NP19	2377916-66-8	98%
T36900	PD-1/PD-L1-IN-NP19 is a PD-1/PD-L1 inhibitor, with an IC50 of 12.5 nM for human PD-1/PD-L1 interaction. PD-1/PD-L1-IN-NP19 could activate the immune microenviron...
T12377	PD-1-IN-17	1673560-66-1	98%
T12377	PD-1-IN-17 is an inhibitor of programmed cell death-1 (PD-1). PD-1-IN-17 inhibits 92% splenocyte proliferation at 100 nM.
TP1076L	AUNP-12 acetate		98%
TP1076L	AUNP-12 acetate is a polypeptide inhibitor of PD-1 that is equivalent to PD-1 and PD-2 in inhibiting lymphocyte proliferation and effector fuction, in addition t...
T9616	PD-1/PD-L1-IN-10	2487550-41-2	98%
T9616	PD-1/PD-L1-IN-10 is an orally active PD-1/PD-L1 inhibitor (IC50 of 2.7 nM) with potent anticancer efficacy.
T9908	Pembrolizumab	1374853-91-4
T9908	Pembrolizumab is a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors impairs the ability of HER2 to bind...
T9907	Nivolumab	946414-94-4
T9907	Nivolumab anti-PD-1) is a genetically engineered fully human immunoglobulin Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell ...
T9903	Avelumab	1537032-82-8
T9903	Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody. Avelumab shows potential antibody-dependent cell-mediated cytotoxicity.
T9902	Atezolizumab	1380723-44-3
T9902	Atezolizumab anti-PD-L1) is a fully humanized IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1 but not the interaction of PD...
T9359	PDL-1 cpd 10	T9359	97.68%
T9359	PDL-1 cpd 10 is a novel small molecule PD-L1 inhititor.
T8470	BMS-1001	2113650-03-4	98.89%
T8470	BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction(IC50 : 2.25 nM, in a homogenous time-resolved fluorescence binding assay).
T26859	BMS-8	1675201-90-7	99.06%
T26859	BMS-8 is a novel inhibitor of the PD-1/PD-L1 interaction.
T5697	BMS-1166	1818314-88-3	99.14%
T5697	BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor.
T0844	Sulfamethoxypyridazine	80-35-3	99.3%
T0844	Sulfamethoxypyridazine is a sulfanilamide antibacterial agent.
T6S0071	Fraxinellone	28808-62-0	99.35%
T6S0071	1. Fraxinellone significantly reduced weight loss and diarrhea in mice and alleviated the macroscopic and microscopic signs of the disease. 2. Fraxinellone exhib...
T9651	PD-1/PD-L1-IN-9	2628506-54-5	99.37%
T9651	PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of PD-1/PD-L1 interaction, IC50 = 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells...
T3146	BMS-202	1675203-84-5	99.47%
T3146	PD1-PDL1 inhibitor 2 is an inhibitor of the PD-1 (Programmed death- 1) /PD-Ll (Programmed death-ligand 1) protein/protein interaction, extracted from patent WO/2...
T4696	BMS202 hydrochloride (1675203-84-5(free base))	T4696	99.47%
T4696	PD-1/PD-L1 inhibitor 2 is a small-molecule PD-1/PD-L1 interaction inhibitor (IC50: 18 nM). Biophysical studies demonstrate that BMS202 binds directly to PD-L1. B...
T10565	BMS-1001 hydrochloride	2113650-04-5	99.57%
T10565	BMS-1001 hydrochloride is an orally active inhibitor of human PD-1/PD-L1 immune checkpoint with low-toxicity in cells.BMS-1001 alleviates the inhibitory effect o...
T3468	Tomivosertib	1849590-01-7	99.67%
T3468	eFT508 is a potent, highly selective MNK1 and MNK2 inhibitor with IC50 value of 1-2 nM.
T3655	BMS-1	1675201-83-8	99.86%
T3655	PD1-PD-L1 inhibitor 1 (PD1-PD-L1-IN-1) is an inhibitor of the PD1-PD-L1 protein-protein interaction. It also acts as an immunomodulator. Programmed death ligand ...